Oscar Health (OSCR) is back in focus after first quarter 2026 results showed revenue of US$4,647.19m and net income of US$679m, alongside reaffirmed full year guidance and fresh board and product updates.

The earnings beat, new product launches, and board changes have coincided with strong momentum, with a 47.69% 1 month share price return and a 39.22% 1 year total shareholder return suggesting investors are reassessing Oscar Health’s risk and growth profile.

If Oscar Health’s recent move has caught your attention, this could be a useful moment to see what else is gaining traction in healthcare technology, starting with 28 healthcare AI stocks.

With the share price up 47.69% in a month and full year guidance reaffirmed, the key question now is whether Oscar Health is still trading below what its fundamentals justify, or if the market is already factoring in expectations for future growth.

Most Popular Narrative: 51% Overvalued

Oscar Health’s most followed narrative puts fair value at $15.40, well below the last close of $23.32, which frames today’s rally in a very different light.

Robust digital adoption and AI-driven efficiencies in healthcare are driving Oscar Health's operating cost reductions, such as a $60 million planned administrative cost cut in 2026, which can lead to improved net margins and set the stage for operating profitability.

Oscar Health's strong year-over-year revenue growth (29% in Q2) and consistently rising membership (28% growth, topping 2 million members) demonstrate competitive strength and sustained market demand, supporting top-line revenue expansion.

Curious what kind of revenue ramp, margin shift, and future earnings power have to line up to support that $15.40 figure and the implied re-rating path?

Result: Fair Value of $15.40 (OVERVALUED)

However, there are still a few swing factors that could flip this picture, including the House subpoena inquiry and any shifts in policy related to premium subsidies.

Another View: What The P/S Ratio Is Signalling

The analyst narrative leans on a fair value of $15.40, yet Oscar Health trades on a P/S of 0.5x versus 1.1x for the US Insurance industry and 0.7x as its fair ratio. That discount points to market hesitation, but is it a cushion or a warning sign for you?

To see how that gap between current P/S, peers, and the fair ratio might close in either direction, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and concern in this story is clear, so consider reviewing the data yourself and stress testing your thesis using the 2 key rewards and 1 important warning sign without waiting too long.

Looking for more investment ideas?

If you stop here, you risk missing other stocks that could fit your goals, so widen your lens now and let the data work harder for you.

• Target potential mispricing by scanning a focused set of 51 high quality undervalued stocks that pair solid fundamentals with market hesitation.
• Strengthen capital preservation aims by reviewing 66 resilient stocks with low risk scores built around lower volatility and more resilient profiles.
• Stretch beyond crowded trades by checking a screener containing 21 high quality undiscovered gems that highlights quality companies still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.